Načítá se...
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
Abstract The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the s...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Adis, Springer Healthcare
2019-08-01
|
| Edice: | Oncology and Therapy |
| Témata: | |
| On-line přístup: | http://link.springer.com/article/10.1007/s40487-019-00098-w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|